Psoriasis Clinical Trial
Post Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System
Summary
This study is a multicenter, prospective, non-randomized, non-controlled post-market clinical follow-up study. The primary objective of this study is to confirm the safety and performance of the A.L.P.S. Proximal Humerus Plating System applied in proximal humerus fracture treatment.
Full Description
The A.L.P.S. Proximal Humerus Plating System was developed to provide another surgical option for proximal humerus fracture fixation. The aim of the A.L.P.S. Proximal Humerus Plating System is to provide increased fracture stability while simultaneously increasing range of motion and decreasing the likelihood of screw perforation.
A minimum of 7 and maximum of 10 sites globally will be involved in this study. This number of clinical sites will allow for a better generalization of study data as well as allow for consistency to be developed across multiple regions. 135 implants will be included into the study. Each site will be allowed to enroll 27 humeri. Enrollment is competitive. All potential study subjects will be required to participate in the Informed Consent process.
Eligibility Criteria
Inclusion Criteria:
Patient must be 18 years of age or older.
Patient must have a primary proximal humerus fracture (Orthopaedic Trauma Association/ American Orthopedic 11-A, B, C) requiring surgical intervention and be eligible for fixation by plate and screws.
Patients with failed conservative treatment within 3 weeks since injury.
Patient must be able and willing to complete the protocol required follow-up.
Patient must have a signed Institutional Review Board/Ethics Committee approved informed consent.
Patient must be in a good nutritional state
Exclusion Criteria:
Delay of surgery for more than 3 weeks.
Tumor induced fractures
Patient is a prisoner.
Pregnancy/ breast feeding
Patient is a current alcohol or drug abuser.
Patient has a mental or neurologic condition that will not allow for proper informed consent and/or participation in follow-up program.
Patient has an active infection.
Patient conditions including limitations in blood supply, obesity, or insufficient quantity or quality of bone stock.
Patient is sensitive to foreign body material.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 2 Locations for this study
Tampa Florida, 33637, United States
Montréal Quebec, H3G 1, Canada More Info
Principal Investigator
Sub-Investigator
Sub-Investigator
How clear is this clinincal trial information?